Alport Syndrom Market wird von Drug Class (ACE Inhibitors, ARBs, SGLT2 Inhibitors, Emerging Therapies), By Disease Type (X-linked Alport Syndrome (XLAS), Autosomal Recess ....
Zu den wichtigsten Akteuren im Alport-Syndrommarkt gehören Eloxx Pharmaceuticals, Chinook Therapeutics, Travere Therapeutics, Reata Pharmaceuticals, Bayer, River 3 Renal Corp, Calliditas Therapeutics, Novartis, Evotec, Genzyme Corp, TMC Pharma Services Ltd und Shanghai Kinderklinik.
Alport Syndrom Market